Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 29Thoracic 2Head & Neck 2Genitourinary 2Dermatologic 2Other solid neoplasm 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Carcinoma, Renal Cell 7Melanoma 5Head and Neck Neoplasms 5Triple Negative Breast Neoplasms 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Carcinoma, Transitional Cell 3Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Mesothelioma, Malignant 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Merkel Cell 1Bites and Stings 1

Interventions

pembrolizumab 23Nivolumab 19atezolizumab 9Specimen Handling 8Ipilimumab 8Cyclophosphamide 8Magnetic Resonance Spectroscopy 6fludarabine 5cabozantinib 5Sorafenib 5sargramostim 4Trastuzumab 4Sunitinib 4Bevacizumab 4lenvatinib 3durvalumab 3avelumab 3X-Rays 3Paclitaxel 3Fluorodeoxyglucose F18 3Docetaxel 3Albumin-Bound Paclitaxel 3ulixertinib 2spartalizumab 2relatlimab 2regorafenib 2palbociclib 2epacadostat 2enzalutamide 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Immune Checkpoint Inhibitors × Genitourinary × Clear all
NCT07405086 2026-05-22

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

OHSU Knight Cancer Institute

Phase 4 Recruiting
160 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡